SARS-CoV-2 is primarily an airborne infection of the upper respiratory tract, which on
reaching the lungs causes the severe acute respiratory disease, COVID-19. Its first contact …

As the COVID-19 pandemic has evolved during the past years, interactions between human
immune systems, rapidly mutating and selected SARS-CoV-2 viral variants, and effective …

Infectious virus shedding from individuals infected with severe acute respiratory syndrome-
coronavirus 2 (SARS-CoV-2) is used to estimate human-to-human transmission risk. Control …

Systemic and mucosal humoral immune responses are crucial to fight respiratory viral
infections in the current pandemic of COVID-19 caused by the SARS-CoV-2 virus. During …

Each severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant renews
concerns about decreased vaccine neutralization weakening efficacy. However, while …

Vaccination against an airborne pathogen is very effective if it induces also the development
of mucosal antibodies that can protect against infection. The mRNA‐based vaccine …

In early 2020, a global emergency was upon us in the form of the coronavirus disease 2019
(COVID‐19) pandemic. While horrific in its health, social and economic devastation, one …

Since the introduction of efficient vaccines anti-SARS-CoV-2, antibody quantification
becomes increasingly useful for immunological monitoring and COVID-19 control. In several …

Background SARS-CoV-2 transmission mainly occurs through exposure of the upper airway
mucosa to infected secretions such as saliva, which are excreted by an infected person …

Background Oral fluid (hereafter, saliva) is a non-invasive and attractive alternative to blood
for SARS-CoV-2 IgG testing; however, the heterogeneity of saliva as a matrix poses …